Summary:
A randomized, placebo-controlled, double- controlled, double-blind phase 3 clinical study to investigate the long tern safety of fezolinetant in women suffering from vasomotor symptoms (hot flashes) associated with menopause.
Qualified Participants Must:
• Be a female between the ages of 40 to 65
•
Suffer from several hot flashes or night sweats a day
•
Be menopausal
Qualified Participants May Receive:
Free medical care
Free treatment
Free medication
Compensation for time and travel